As of January 22, 2025, ACELYRIN (SLRN) has a market cap of $0.20 billion USD. According to our data, ACELYRIN is ranked No.7091 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.20 B |
-35.67%
|
Dec 31, 2024 | $0.32 B |
-57.91%
|
Dec 29, 2023 | $0.75 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
BioMarin Pharmaceutical
BMRN
|
$11.82 B |
0.000 M
|
USA
|
Incyte
INCY
|
$13.95 B |
-0.000 M
|
USA
|
Alnylam Pharmaceuticals
ALNY
|
$34.38 B |
-0.000 M
|
USA
|
Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
Blueprint Medicines
BPMC
|
$7.06 B |
-0.000 M
|
USA
|
Exelixis
EXEL
|
$9.39 B |
0.000 M
|
USA
|
Ionis Pharmaceuticals
IONS
|
$5.13 B |
-0.000 M
|
USA
|
Ultragenyx
RARE
|
$3.97 B |
0.000 M
|
USA
|
Market Cap | = | SLRN Stock Price | * | SLRN Shares Outstanding |
= | $2.02 | * | 0.10 B | |
= | $0.20 B |